A Phase 1b study of venetoclax and gilteritinib in patients with Relapsed/Refractory AML also demonstrated efficacy, with 50% of FLT3-mutant patients achieving composite complete remission and an additional 40% reaching a morphologic leukemia-free state [21]. This evidence concerns the gene FLT3 and leukemia.